

Venture Corporation Limited

Earnings close to record levels

SINGAPORE | TECHNOLOGY MANUFACTURING | 1Q22 UPDATE

- 1Q22 PAT rose 28% YoY to S\$84mn and beat our estimates by 10%. It was the 2nd highest Mar quarter for Venture. PAT was 23% of our FY22e forecast.
- Venture has coped well with supply chain challenges through a strong balance sheet to bulk up on inventories and re-design of products with new components.
- Outlook remains upbeat with customers committing to six to 12 months of visibility. We also believe new products especially life science are gaining more traction. Despite the earnings beat, we maintain our FY22e PATMI. We are incorporating a buffer as the slowing macro environment remains a concern. The target price of \$\$20.00 is unchanged and based on 16x PE FY22e, its 5-year average. Our recommendation is upgraded from ACCUMULATE to BUY. The current share price offers a 5% dividend yield with an attractive unlevered ROE of 13% and a net cash balance sheet of \$\$808mn.

Results at a glance

| SGDmn | 1Q22 | 1Q21 | YoY | Comments |
|-------------|-------|-------|--------|--|
| Revenue | 889.3 | 686.7 | 29.5% | 2nd highest March quarter revenue. |
| PBT | 102.6 | 75.0 | 36.8% | |
| PBT margin | 11.5% | 10.9% | 0.6% | |
| Net profiit | 84.0 | 65.3 | 28.6% | |
| Net margin | 9.4% | 9.5% | -0.1% | |
| Net cash | 815.1 | 989.6 | -17.6% | Inventory was up S\$462mn YoY to S\$1.1bn. |

Source: Company, PSR #Note – Only selected financials are provided in the 1Q22 update.

The Positive

+ Revenue building up momentum. Revenue momentum has picked up since 4Q21. Revenue is recovering to pre-pandemic levels as factory closures and supply chain disruptions over the past two years start to ease. Due to long lead times and shortages, Venture has managed to re-design products with alternative components.

The Negative

- Inventories spiked almost 70% YoY to \$\$1.1bn. To support customer orders, Venture needs to hold inventories of semiconductors, materials and other components. It is a near-term drag on working capital. Both receivables and inventory are up \$\$680mn YoY. The additional working capital required was \$370mn to fund the \$283mn increase in revenue over the past 12 months as payables jumped by \$\$305mn. Net cash dropped to \$\$815mn from \$\$989mn a year ago.

Outlook

We expect FY22e to be a recovery year for Venture as: (i) There is order visibility as customers make longer-term commitments to ensure supply; (ii) Growth is broad-based across six of their seven key industries; (iii) Rebound from last year's factory shutdown in Malaysia; and (iv) New products gaining more traction with customers, namely in life science and lifestyle and wellness.

Upgrade to BUY from ACCUMULATE with an unchanged TP of S\$20.00

Our FY22e revenue and earnings forecast are unchanged.



3 May 2022

BUY (Upgraded)

| TOTAL RETURN | 21.6% |
|---------------|-----------|
| TARGET PRICE | SGD 20.00 |
| FORECAST DIV | SGD 0.85 |
| CLOSING PRICE | SGD 17.15 |

COMPANY DATA

| BLOOMBERG CODE: | VMS SP |
|-------------------------------|---------------|
| O/S SHARES (MN): | 291 |
| MARKET CAP (USD mn / SGD mn): | 3607/4985 |
| 52 - WK HI/LO (SGD) : | 20.23 / 16.24 |
| 3M Average Daily T/O (mn): | 1.21 |

MAJOR SHAREHOLDERS

| Wong Ngit Liong | 7.1% |
|-----------------|------|
| Schroders PLC | 6.8% |
| BlackRock Inc | 5.9% |

PRICE PERFORMANCE (%)

| | 1MTH | змтн | YTD |
|------------|-------|-------|-------|
| COMPANY | (2.4) | (2.6) | (6.3) |
| STI RETURN | (0.8) | 4.4 | 8.7 |

RICE VS. STI



Source: Bloomberg, PSR

KEY FINANCIALS

| Y/E Dec, SGD mn | FY20 | FY21 | FY22e | FY23e |
|-----------------|-------|-------|-------|-------|
| Revenue | 3,013 | 3,107 | 3,403 | 3,641 |
| EBITDA | 375.4 | 387.7 | 449.8 | 466.0 |
| Net Profit | 297.3 | 312.1 | 363.1 | 372.7 |
| P/E (X) | 16.7 | 16.0 | 13.7 | 13.4 |
| Dividend Yield | 4.4% | 4.4% | 5.0% | 5.0% |
| ROE | 11.5% | 11.5% | 12.7% | 12.4% |
| ROA | 9.2% | 8.6% | 9.7% | 9.5% |

Source: Company, PSR

VALUATION METHOD

16x PE Multiple FY22e

Paul Chew (+65 6212 1851) Head Of Research

paulchewkl@phillip.com.sg



Financials

| Income Statement |
|------------------|
|------------------|

| Y/E Dec, SGD '000 | FY19 | FY20 | FY21 | FY22e | FY23e |
|-----------------------------|-----------|-----------|-----------|-----------|-----------|
| Revenue | 3,633,431 | 3,012,894 | 3,107,457 | 3,402,665 | 3,640,852 |
| Gross profit | 907,505 | 796,450 | 811,973 | 913,414 | 966,326 |
| EBITDA | 447,488 | 375,384 | 387,711 | 449,832 | 466,029 |
| Depreciation & Amortisation | (38,692) | (41,607) | (36,879) | (39,860) | (42,855) |
| EBIT | 408,796 | 333,777 | 350,832 | 409,972 | 423,174 |
| Net Finance Inc/(Exp) | (523) | (470) | (423) | 0 | 0 |
| Profit before tax | 420,024 | 342,830 | 359,588 | 419,909 | 433,553 |
| Taxation | (56,643) | (45,426) | (47,266) | (56,688) | (60,697) |
| PATMI | 363,130 | 297,325 | 312,051 | 363,071 | 372,705 |

Balance Sheet

| Y/E Dec, SGD '000 | FY19 | FY20 | FY21 | FY22e | FY23e |
|-------------------------------|-----------|-----------|-----------|-----------|-----------|
| ASSETS | | | | | |
| PPE | 231,739 | 226,704 | 215,169 | 205,060 | 196,976 |
| Others | 697,170 | 689,533 | 682,571 | 682,522 | 682,492 |
| Total non-current assets | 928,909 | 916,237 | 897,740 | 887,582 | 879,468 |
| Receivables | 916,237 | 721,377 | 860,125 | 983,626 | 941,093 |
| Cash | 714,467 | 928,740 | 807,934 | 905,458 | 1,181,914 |
| Inventories | 706,150 | 656,453 | 1,049,429 | 952,746 | 910,213 |
| Others | 8,482 | 16,760 | 20,033 | 20,033 | 20,033 |
| Total current assets | 2,345,336 | 2,323,330 | 2,737,521 | 2,861,864 | 3,053,253 |
| Total Assets | 3,274,245 | 3,239,567 | 3,635,261 | 3,749,445 | 3,932,720 |
| | | | | | |
| LIABILITIES | | | | | |
| Accounts payables | 659,981 | 555,784 | 799,952 | 768,841 | 811,714 |
| Tax payable | 34,274 | 34,187 | 25,764 | 25,764 | 25,764 |
| Bank Ioan | 1,058 | 0 | 0 | 0 | 0 |
| Others | 49,380 | 36,152 | 73,052 | 73,052 | 73,052 |
| Total current liabilities | 755,294 | 636,228 | 907,499 | 876,388 | 919,261 |
| Deferred tax liabilites | 3,040 | 3,365 | 3,512 | 3,512 | 3,512 |
| Total non-current liabilities | 20,358 | 14,210 | 8,312 | 8,312 | 8,312 |
| Total Liabilities | 775,652 | 650,438 | 915,811 | 884,700 | 927,573 |
| | | | | | |
| EQUITY | | | | | |
| Non-controlling Interests | 2,395 | 2,679 | 3,098 | 3,248 | 3,398 |
| Shareholder's Equity | 2,496,198 | 2,586,450 | 2,716,352 | 2,861,498 | 3,001,749 |

Per share data (SGD Cents)

| Y/E Dec | FY19 | FY20 | FY21 | FY22e | FY23e |
|---------------|-------|-------|-------|-------|-------|
| EPS, reported | 125.3 | 102.5 | 107.4 | 125.0 | 128.3 |
| DPS | 70.0 | 75.0 | 75.0 | 85.0 | 85.0 |
| BVPS | 8.6 | 8.9 | 9.4 | 9.9 | 10.4 |

Valuation Ratios

| Valuation Natios | | | | | |
|-----------------------|-------|--------|-------|-------|-------|
| Y/E Dec | FY19 | FY20 | FY21 | FY22e | FY23e |
| P/E (X) | 13.7 | 16.7 | 16.0 | 13.7 | 13.4 |
| P/B (X) | 2.0 | 1.9 | 1.8 | 1.7 | 1.7 |
| EV/EBITDA (X) | 9.5 | 10.8 | 10.7 | 9.0 | 8.1 |
| Growth & Margins | | | | | |
| <u>Growth</u> | | | | | |
| Revenue | 4.3% | -17.1% | 3.1% | 9.5% | 7.0% |
| EBITDA | -1.4% | -16.1% | 3.3% | 16.0% | 3.6% |
| EBIT | -3.4% | -18.4% | 5.1% | 16.9% | 3.2% |
| PATMI | -1.9% | -18.1% | 5.0% | 16.3% | 2.7% |
| <u>Margins</u> | | | | | |
| Gross margin | 25.0% | 26.4% | 26.1% | 26.8% | 26.5% |
| EBITDA margin | 12.3% | 12.5% | 12.5% | 13.2% | 12.8% |
| EBIT margin | 11.3% | 11.1% | 11.3% | 12.0% | 11.6% |
| Net profit margin | 10.0% | 9.9% | 10.0% | 10.7% | 10.2% |
| Key Ratios | | | | | |
| ROE | 14.5% | 11.5% | 11.5% | 12.7% | 12.4% |
| ROA | 11.1% | 9.2% | 8.6% | 9.7% | 9.5% |
| Dividend Yield | 4.1% | 4.4% | 4.4% | 5.0% | 5.0% |
| Dividend Payout Ratio | 55.8% | 73.2% | 69.8% | 68.0% | 66.3% |

| Cash Flow | | | | | |
|---------------------------|-----------|-----------|-----------|-----------|-----------|
| Y/E Dec, SGD '000 | FY19 | FY20 | FY21 | FY22e | FY23e |
| <u>CFO</u> | | | | | |
| Profit before tax | 420,024 | 342,830 | 359,588 | 419,909 | 433,553 |
| Adjustments | 28,504 | 40,938 | 40,141 | 31,922 | 34,435 |
| WC changes | (156,795) | 114,872 | (241,543) | (57,930) | 127,940 |
| Cash generated from ops | 291,733 | 498,640 | 158,186 | 393,901 | 595,928 |
| Tax paid | (61,509) | (45,020) | (55,928) | (56,688) | (60,697) |
| Others | (523) | (470) | (423) | 0 | 0 |
| Cashflow from ops | 229,701 | 453,150 | 101,835 | 337,213 | 535,231 |
| <u>CFI</u> | | | | | |
| CAPEX, net | (35,071) | (27,768) | (10,793) | (30,000) | (35,000) |
| Others | 10,329 | 7,880 | 8,704 | 8,237 | 8,679 |
| Cashflow from investments | (24,742) | (19,888) | (2,089) | (21,763) | (26,321) |
| <u>CFF</u> | | | | | |
| Share issuance, net | 7,698 | 15,554 | 5,724 | 0 | 0 |
| Loans, net of repayments | (4,021) | (1,120) | 0 | 0 | 0 |
| Dividends | (201,694) | (216,900) | (217,822) | (217,926) | (232,454) |
| Others | (6,969) | (11,786) | (13,623) | 0 | 0 |
| Cashflow from financing | (204,986) | (214,252) | (225,721) | (217,926) | (232,454) |
| Net change in cash | (27) | 219,010 | (125,975) | 97,524 | 276,455 |
| CCE, end | 714,467 | 928,740 | 807,934 | 905,458 | 1,181,914 |

Source: Company, Phillip Securities Research (Singapore) Estimates





| PSR Rating System | | |
|-----------------------|----------------|--------|
| Total Returns | Recommendation | Rating |
| > +20% | Buy | 1 |
| > +20% +5% to +20% | Accumulate | 2 |
| -5% to +5% | Neutral | 3 |
| -5% to -20% | Reduce | 4 |
| < -20% | Sell | 5 |
| Domonko | | |

We do not base our recommendations entirely on the above quantitative return bands. We consider qualitative factors like (but not limited to) a stock's risk reward profile, market sentiment, recent rate of share price appreciation, presence or absence of stock price catalysts, and speculative undertones surrounding the stock, before making our final recommendation



Contact Information (Research Team)

Head of Research

Paul Chew-paulchewkl@phillip.com.sg Consumer | Industrial | Conglomerates

Terence Chua - terencechuatl@phillip.com.sg

Property | REITs

Natalie Ong - natalie ongpf@phillip.com.sg

US Technology Analyst (Hardware)

Timothy Ang - timothyang@phillip.com.sg

US Technology Analyst (Software/Services)

Ambrish Shah - amshah@phillipcapital.in

Banking & Finance

Research Admin

Glenn Thum - glennthumjc@phillip.com.sg

US Technology Analyst (Internet)

Qystina Azli - qystina@phillip.com.sg

Jonathan Woo - jonathanwookj@phillip.com.sg

HONG KONG

Phillip Securities (HK) Ltd

11/F United Centre 95 Queensway

Hong Kong Tel +852 2277 6600

Fax +852 2868 5307

Websites: www.phillip.com.hk

Credit Analyst

Small-Mid Cap

Shawn Sng - shawnsngkh@phillip.com.sg

Vivian Ye - yeqw@phillip.com.sg

Contact Information (Regional Member Companies) MALAYSIA

Phillip Capital Management Sdn Bhd

B-3-6 Block B Level 3 Megan Avenue II, No. 12, Jalan Yap Kwan Seng, 50450 Kuala Lumpur

Tel +603 2162 8841 Fax +603 2166 5099 Website: www.poems.com.my

INDONESIA

PT Phillip Securities Indonesia

ANZ Tower Level 23B, JI Jend Sudirman Kav 33A Jakarta 10220 - Indonesia Tel +62-21 5790 0800 Fax +62-21 5790 0809

Website: www.phillip.co.id

FRANCE

King & Shaxson Capital Limited

3rd Floor, 35 Rue de la Bienfaisance 75008

Paris France

Tel +33-1 45633100

Fax +33-1 45636017

Website: www.kingandshaxson.com

AUSTRALIA

Phillip Capital Limited

Level 10,330 Collins Street

Melbourne, Victoria 3000, Australia

Tel +61-03 8633 9803

Fax +61-03 8633 9899

Website: www.phillipcapital.com.au

CHINA

Phillip Financial Advisory (Shanghai) Co Ltd

No 550 Yan An East Road, Ocean Tower Unit 2318, Postal code 200001 Tel +86-21 5169 9200 Fax +86-21 6351 2940

Website: www.phillip.com.cn

THAILAND

UNITED STATES

Website: www.phillipusa.com

TURKEY PhillipCapital Menkul Degerler

Dr. Cemil Bengü Cad. Hak Is Merkezi No. 2 Kat. 6A Caglayan 34403 Istanbul, Turkey Tel: 0212 296 84 84 Fax: 0212 233 69 29

Website: www.phillipcapital.com.tr

UNITED KINGDOM King & Shaxson Capital Limited

6th Floor, Candlewick House, 120 Cannon Street, London, EC4N 6AS Tel +44-20 7426 5950

Fax +44-20 7626 1757

Website: www.kingandshaxson.com

CAMBODIA Phillip Bank Plc

Ground Floor of B-Office Centre,#61-64, Norodom Blvd Corner Street 306, Sangkat Boeung Keng Kang 1, Khan Chamkamorn, Phnom Penh, Cambodia

Tel: 855 (0) 7796 6151/855 (0) 1620 0769

Website: www.phillipbank.com.kh

DUBAI

Phillip Futures DMCC

Member of the Dubai Gold and Commodities Exchange (DGCX) Unit No 601, Plot No 58, White Crown Bldg, Sheikh Zayed Road, P.O.Box 212291

Dubai-UAE

Tel: +971-4-3325052 / Fax: +971-4-3328895

Singapore 179101 Tel +65 6533 6001 Fax +65 6535 6631

SINGAPORE

Raffles City Tower

250, North Bridge Road #06-00

Phillip Securities Pte Ltd

JAPAN Phillip Securities Japan, Ltd.

Website: www.poems.com.sg

4-2 Nihonbashi Kabuto-cho Chuo-ku, Tokyo 103-0026 Tel +81-3 3666 2101 Fax +81-3 3666 6090

Website: www.phillip.co.jp

Phillip Securities (Thailand) Public Co. Ltd

15th Floor, Vorawat Building, 849 Silom Road, Silom, Bangrak, Bangkok 10500 Thailand Tel +66-2 6351700 / 22680999 Fax +66-2 22680921 Website <u>www.phillip.co.th</u>

Phillip Capital Inc

141 W Jackson Blvd Ste 3050 The Chicago Board of Trade Building Chicago, IL 60604 USA Tel +1-312 356 9000 Fax +1-312 356 9005

INDIA

PhillipCapital (India) Private Limited

No.1, 18th Floor, Urmi Estate 95, Ganpatrao Kadam Marg Lower Parel West, Mumbai 400-013 Maharashtra, India

Tel: +91-22-2300 2999 / Fax: +91-22-2300 2969 Website: www.phillipcapital.in



Important Information

This report is prepared and/or distributed by Phillip Securities Research Pte Ltd ("Phillip Securities Research"), which is a holder of a financial adviser's license under the Financial Advisers Act, Chapter 110 in Singapore.

By receiving or reading this report, you agree to be bound by the terms and limitations set out below. Any failure to comply with these terms and limitations may constitute a violation of law. This report has been provided to you for personal use only and shall not be reproduced, distributed or published by you in whole or in part, for any purpose. If you have received this report by mistake, please delete or destroy it, and notify the sender immediately.

The information and any analysis, forecasts, projections, expectations and opinions (collectively, the "Research") contained in this report has been obtained from public sources which Phillip Securities Research believes to be reliable. However, Phillip Securities Research does not make any representation or warranty, express or implied that such information or Research is accurate, complete or appropriate or should be relied upon as such. Any such information or Research contained in this report is subject to change, and Phillip Securities Research shall not have any responsibility to maintain or update the information or Research made available or to supply any corrections, updates or releases in connection therewith.

Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this report are as of the date in dicated and are subject to change at any time without prior notice. Past performance of any product referred to in this report is not indicative of future results.

This report does not constitute, and should not be used as a substitute for, tax, legal or investment advice. This report should not be relied upon exclusively or as authoritative, without further being subject to the recipient's own independent verification and exercise of judgment. The fact that this report has been made available constitutes neither a recommendation to enter into a particular transaction, nor a representation that any product described in this report is suitable or appropriate for the recipient. Recipients should be aware that many of the products, which may be described in this report involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made, unless all such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks.

Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of any product. Any decision to purchase any product mentioned in this report should take into account existing public information, including any registered prospectus in respect of such product.

Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may provide an array of financial services to a large number of corporations in Singapore and worldwide, including but not limited to commercial / investment banking activities (including sponsorship, financial advisory or underwriting activities), brokerage or securities trading activities. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have participated in or invested in transactions with the issuer(s) of the securities mentioned in this report, and may have performed services for or solicited business from such issuers. Additionally, Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may have provided advice or investment services to such companies and investments or related investments, as may be mentioned in this report.

Phillip Securities Research or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report may, from time to time maintain a long or short position in securities referred to herein, or in related futures or options, purchase or sell, make a marketin, or engage in any other transaction involving such securities, and earn brokerage or other compensation in respect of the foregoing. Investments will be denominated in various currencies including US dollars and Euro and thus will be subject to any fluctuation in exchange rates between US dollars and Euro or foreign currencies and the currency of your own jurisdiction. Such fluctuations may have an adverse effect on the value, price or income return of the investment.

To the extent permitted by law, Phillip Securities Research, or persons associated with or connected to Phillip Securities Re search, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may at any time engage in any of the above activities as set out above or otherwise hold an interest, whether material or not, in respect of companies and investments or related investments, which may be mentioned in this report. Accordingly, information may be available to Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, which is not reflected in this report, and Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited to its officers, directors, employees or persons involved in the issuance of this report, may, to the extent permitted by law, have acted upon or used the information prior to or immediately following its publication. Phillip Securities Research, or persons associated with or connected to Phillip Securities Research, including but not limited its officers, directors, employees or persons involved in the issuance of this report, may have issued other material that is inconsistent with, or reach different conclusions from, the contents of this report.

The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities Research to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction.

This report is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. The products mentioned in this report may not be suitable for all investors and a person receiving or reading this report should seek advice from a professional and financial adviser regarding the legal, business, financial, tax and other aspects including the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, before making a commitment to invest in any of such products.

This report is not intended for distribution, publication to or use by any person in any jurisdiction outside of Singapore or any other jurisdiction as Phillip Securities Research may determine in its absolute discretion.

IMPORTANT DISCLOSURES FOR INCLUDED RESEARCH ANALYSES OR REPORTS OF FOREIGN RESEARCH HOUSES

Where the report contains research analyses or reports from a foreign research house, please note:

- (i) recipients of the analyses or reports are to contact Phillip Securities Research (and not the relevant foreign research house) in Singapore at 250 North Bridge Road, #06-00 Raffles City Tower, Singapore 179101, telephone number +65 6533 6001, in respect of any matters arising from, or in connection with, the analyses or reports; and
- (ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore who is not an accredited investor, expert investor or institutional investor, Phillip Securities Research accepts legal responsibility for the contents of the analyses or reports.